GENinCode plc Acquires Abcodia Limited (ROCA Test)
September 28, 2022
Oxford-based GENinCode plc has acquired Cambridge-based Abcodia Limited and its Risk of Ovarian Cancer Algorithm (ROCA) test on an earnout basis with a maximum consideration of £1 million. The acquisition marks GENinCode’s first entry into oncology as it plans to accelerate ROCA revenues in the UK and pursue market entry in the United States and European Union.
- Buyers
- GENinCode plc
- Targets
- Abcodia Limited
- Industry
- Biotechnology
- Location
- Cambridgeshire, United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
QIAGEN Acquires Genoox
May 12, 2025
Biotechnology
QIAGEN has signed a definitive agreement to acquire Genoox, the developer of the AI-powered Franklin clinical genomics platform, for $70 million in cash plus up to $10 million in milestone payments. The acquisition adds Genoox's cloud-based AI interpretation capabilities to QIAGEN Digital Insights, expanding QIAGEN's clinical genomics and diagnostic software offerings for labs and healthcare organizations worldwide.
-
SeqOne Acquires Congenica
September 2, 2025
Software
SeqOne has acquired Congenica, a UK clinical genomics software company spun out of the Wellcome Sanger Institute, creating one of the largest pure‑play genomics software firms serving over 160 laboratories in 30+ countries. The combined business will integrate SeqOne's AI-driven NGS analysis platform with Congenica's clinical decision‑support tools to accelerate rare disease diagnoses and personalized cancer therapies while expanding SeqOne's UK presence.
-
Roche Acquires Poseida Therapeutics
November 28, 2024
Biotechnology
Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.
-
IBA Acquires ORA Group to Expand Nuclear Medicine Capabilities
December 19, 2025
Medical Devices
Ion Beam Applications S.A. (IBA) has acquired ORA Group (ORA - Optimized Radiochemical Applications SRL and OOC) to strengthen its leadership in nuclear medicine and radiochemistry. The cash-free, debt-free transaction (total consideration €15–20 million) is financed from IBA’s own funds and existing credit facilities and is immediately accretive to IBA Technologies’ revenue and EBITDA; ORA founder Vincent Tadino will continue with the combined business as CTO.
-
CircleCI Acquires Ponicode
March 9, 2022
Software
CircleCI has acquired Ponicode, a Paris-based AI-powered testing platform, to integrate AI-driven test generation and analysis into its CI/CD offering. The acquisition expands CircleCI's product capabilities and engineering presence in France, aiming to improve developer productivity by shifting advanced testing and intelligence earlier into the development workflow.
-
CUBE Acquires Acin
June 19, 2025
Software
CUBE has acquired Acin, a London‑headquartered RegTech provider of AI-based operational risk and controls analytics, to integrate operational risk capabilities into CUBE’s regulatory compliance platform. The deal creates a unified RegPlatform combining regulatory intelligence and non-financial risk analytics to serve financial institutions globally; financial terms were not disclosed.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.